Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Shingles Vaccine Recombinant, Adjuvant
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : REC610 (recombinant shingles vaccine) is a recombinant herpes zoster vaccine which is under phase 1 clinical trials. It is a recombinant protein technology which can induce high levels of gE-specific CD4+ T cell responses and IgG antibody.
Product Name : REC610
Product Type : Vaccine
Upfront Cash : Inapplicable
December 28, 2023
Lead Product(s) : Shingles Vaccine Recombinant, Adjuvant
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Shingles Vaccine Recombinant, Adjuvant
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : REC610 is a recombinant herpes zoster vaccine using recombinant protein technology similar to Shingrix® and showing immunogenicity not inferior to Shingrix® in animal studies.
Product Name : REC610
Product Type : Vaccine
Upfront Cash : Inapplicable
July 26, 2023
Lead Product(s) : Shingles Vaccine Recombinant, Adjuvant
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Shingles Vaccine Recombinant, Adjuvant
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : REC610 has favorable immunogenicity and can induce high levels of gE-specific CD4+ T cell responses and IgG antibody, and its immune response is non-inferior to the controlled vaccine Shingrix.
Product Name : REC610
Product Type : Vaccine
Upfront Cash : Inapplicable
February 13, 2023
Lead Product(s) : Shingles Vaccine Recombinant, Adjuvant
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Shingles Vaccine Recombinant, Adjuvant
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preclinical studies have shown that REC610 has favorable immunogenicity and can induce high levels of gE-specific CD4+T cell responses and IgG antibody, and its immune response is non-inferior to the controlled vaccine Shingrix®.
Product Name : REC610
Product Type : Vaccine
Upfront Cash : Inapplicable
December 19, 2022
Lead Product(s) : Shingles Vaccine Recombinant, Adjuvant
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Quadrivalent HPV Vaccine Recombinant, Adjuvant
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The REC604a (adjuvanted recombinant quadrivalent HPV vaccine) is equipped with the novel adjuvanted BFA04 independently developed by the Company, which aims to reduce the dose of vaccination by enhancing the immunogenicity and cross-protection effects.
Product Name : REC604a
Product Type : Vaccine
Upfront Cash : Inapplicable
October 27, 2022
Lead Product(s) : Quadrivalent HPV Vaccine Recombinant, Adjuvant
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 9-Valent HPV Vaccine Recombinant
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Recbio Announces Phase III Trial Progress of Recombinant HPV 9-valent Vaccine
Details : Completed Phase I clinical data of REC603 (Recombinant Nine-valent HPV Vaccine) shows that safe and well tolerated with favorable immunogenicity profile. REC603 adopts H. polymorpha expression system to achieve high-yield and stable expression of HPV vir...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 08, 2022
Lead Product(s) : 9-Valent HPV Vaccine Recombinant
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recov
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ReCOV is a recombinant COVID-19 vaccine developed by the company using new adjuvants, protein engineering platforms and other technology platforms. Its adjuvant uses the self-developed new adjuvant BFA03.
Product Name : Recov
Product Type : Vaccine
Upfront Cash : Inapplicable
August 19, 2022
Lead Product(s) : Recov
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recov
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Approval Of The Comparative Study Between ReCOV And mRNA Vaccines By FDA In The Philippines
Details : ReCOV is a recombinant COVID-19 vaccine being developed by the Company with its technology platforms including the novel adjuvant and protein engineering platforms, and the adjuvant used therein is the Company's self-developed novel adjuvant BFA03.
Product Name : Recov
Product Type : Vaccine
Upfront Cash : Inapplicable
March 08, 2022
Lead Product(s) : Recov
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Protein COVID-19 Vaccine Recombinant
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Trial Approval For ReCOV In The PRC And The Overseas Clinical Trial Progress Of ReCOV
Details : ReCOV (Recombinant Protein COVID-19 Vaccine), (CHO Cell) is a combination of new adjuvants, protein engineering and other technology platform to thoroughly optimize the vaccine.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
February 05, 2022
Lead Product(s) : Protein COVID-19 Vaccine Recombinant
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recov
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Recbio, together with Jiangsu Provincial Center for Disease Control and Prevention ("Jiangsu CDC") and Taizhou Medical New & High-tech Industrial Development Zone, jointly developed a recombinant two-component COVID-19 vaccine(ReCOV).
Product Name : Recov
Product Type : Vaccine
Upfront Cash : Inapplicable
November 16, 2021
Lead Product(s) : Recov
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable